多发性硬化症的治疗满意度
Treatment satisfaction in multiple sclerosis.
作者信息
Glanz Bonnie I, Musallam Alexander, Rintell David J, Chitnis Tanuja, Weiner Howard L, Healy Brian C
机构信息
Department of Neurology, Harvard Medical School, Boston, MA, USA (BIG, DJR, TC, HLW, BCH); Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA (BIG, AM, DJR, TC, HLW, BCH); and Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA (BCH).
出版信息
Int J MS Care. 2014 Summer;16(2):68-75. doi: 10.7224/1537-2073.2013-021.
BACKGROUND
Disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) are associated with inconvenient methods of administration, significant side effects, and low adherence rates. This study was undertaken to compare treatment satisfaction in MS patients treated with interferon beta-1a intramuscular (IFNβ-1a IM), interferon beta-1a subcutaneous (IFNβ-1a SC), glatiramer acetate (GA), and natalizumab (NTZ), and to examine the associations between treatment satisfaction ratings and adherence to therapy.
METHODS
Two hundred twenty-six treated MS patients completed the Treatment Satisfaction Questionnaire for Medicine. Multivariable models were used to compare treatment satisfaction across groups.
RESULTS
There were no statistically significant differences in overall treatment satisfaction. The NTZ group reported greater satisfaction with the ability of the medication to treat or prevent MS than the IFNβ-1a IM group. The NTZ group also reported higher overall convenience scores than the IFNβ-1a IM group and greater satisfaction with ease of use of the medication than the interferon and GA groups. Patients in the IFNβ-1a IM group reported less satisfaction with ease of planning when to use the medication than those in the other groups. Convenience was associated with adherence in IFNβ-1a SC- and GA-treated patients, with lower convenience scores associated with lower adherence.
CONCLUSIONS
These results may be useful to MS patients and health-care providers facing decisions about DMT use.
背景
用于治疗多发性硬化症（MS）的疾病修正疗法（DMTs）存在给药方式不便、副作用大以及依从率低等问题。本研究旨在比较接受肌肉注射干扰素β-1a（IFNβ-1a IM）、皮下注射干扰素β-1a（IFNβ-1a SC）、醋酸格拉替雷（GA）和那他珠单抗（NTZ）治疗的MS患者的治疗满意度，并探讨治疗满意度评分与治疗依从性之间的关联。
方法
226例接受治疗的MS患者完成了药物治疗满意度问卷。采用多变量模型比较各组的治疗满意度。
结果
总体治疗满意度无统计学显著差异。与IFNβ-1a IM组相比，NTZ组对药物治疗或预防MS能力的满意度更高。NTZ组的总体便利性得分也高于IFNβ-1a IM组，且与干扰素和GA组相比，对药物易用性的满意度更高。与其他组相比，IFNβ-1a IM组患者对规划用药时间的满意度较低。在接受IFNβ-1a SC和GA治疗的患者中，便利性与依从性相关，便利性得分越低，依从性越低。
结论
这些结果可能对面临DMT使用决策的MS患者和医疗服务提供者有用。
Zotero 插件